568 results about "Bacteriophage" patented technology

The invention relates to the technical field of microorganisms, in particular to nocardia seriolae bacteriophage as well as a composition and application thereof. The name of the nocardia seriolae bacteriophage is RDP-NS002, the nocardia seriolae bacteriophage is preserved in the China General Microbiological Culture Collection Center on August 25, 2025, and the preservation number of the nocardia seriolae bacteriophage is CGMCC No.46674. The nocardia seriolae bacteriophage is named as RDP-NS002, and the nocardia seriolae bacteriophage is preserved in the China General Microbiological Culture Collection Center on August 25, 2025. The composition comprises the bacteriophage. The bacteriophage or the composition is prepared in the following steps: (1) preparing a product for killing nocardia seriolae; (2) preparing a product for inhibiting nocardia seriola; and (3) application in preparation of a product for preventing and / or treating fish nocardia disease caused by nocardia seriolae. The phage has the characteristics of high thermal stability, high acid-base stability and high splitting rate, has a long-acting inhibition effect, and is beneficial to prevention and treatment of nocardia seriola diseases.

The invention discloses a lytic bacteriophage vBVpaSR40Z and application of the lytic bacteriophage vBVpaSR40Z to prevention and control of vibrio parahaemolyticus in an aquaculture environment. The preservation number of the vibrio parahaemolyticus phage vBVpaSR40Z is as follows: GDMCC No: 67440-B1, and the vibrio parahaemolyticus phage vBVpaSR40Z is The R40Z can be used for cracking multiple strains of vibrio parahaemolyticus and vibrio alginolyticus, has the capability of adapting to an aquaculture environment, and keeps relatively high activity within the range of 4-25 DEG C and pH of 4-10; no virulence gene or drug-resistant gene is detected through genome analysis, and phylogenetic and whole genome comparison shows that the similarity between R40Z and a related phage is lower than a species level threshold value, so that R40Z is a new phage species; the R40Z can obviously inhibit the growth of a host under various infection complex numbers. The R40Z has the advantages of strong splitting capacity, good environmental stability, high genome safety, unique evolutionary characteristics and the like, and is an aquatic vibriosis biological prevention and control bacteriophage with application potential.

The invention relates to the technical field of feed ingredient optimization, in particular to an ingredient optimization and adjustment system for a phage type antibiotic-free feed additive. Comprising the following steps: acquiring multi-dimensional environmental data and antibody content indexes and stress state information of individuals; determining a health index according to the antibody content index and the stress state information; performing batching delay analysis according to the change of the health index, and determining a lag moment; determining an effect coefficient in combination with the lagging time and the health index, determining the influence degree of the environmental data of each dimension on the batching effect, and screening to obtain an influence environmental dimension in combination with the influence degree of the environmental data of all dimensions on the batching effect and the predicted value of the environmental data in the next batch; and adjusting the ratio of additives in the same feeding stage in the next batch based on the influence environment dimension. According to the method, the ingredient adjustment logic can be optimized, and the adaptability of ingredients in a multi-dimensional complex scene is improved.

The invention discloses a lytic bacteriophage for preventing and controlling vibrio in an aquaculture environment. The bacteriophage vBValMR42H belongs to a muscle tail bacteriophage and is insensitive to chloroform, the capsid of the bacteriophage vBValMR42H is free of lipid substances, and the preservation number is GDMCC No: 67434-B1. The bacteriophage has the characteristics of high adsorption speed, short incubation period and high cracking amount, keeps high activity in a wide range of temperature (4-55 DEG C) and pH (2-11), and has strong environmental adaptability. Genome analysis shows that the bacteriophage does not contain virulence factors, antibiotic resistance genes and lyogen related genes, and is high in biological safety. Physical development analysis shows that the method can be divided into a new genus. The bacteriophage R42H has the advantages of high splitting efficiency, good environmental stability, strong specificity, gene safety and the like, and can be used as an ideal biological prevention and control agent for preventing and controlling vibrio alginolyticus diseases in aquaculture.

The invention discloses a vibrio cantoniensis bacteriophage vBVcaSR45Z and an application of the vibrio cantoniensis bacteriophage The invention relates to Vibrio campbelli phage vBVcaSR45Z, which is preserved in Guangdong Microbial Culture Collection Center (GDMCC) on December 8, 2025, the address is Courtyard 100 #, Xianlie Middle Road, Xiaolian District, Guangzhou City, Guangdong Province, the postcode is 510070, and the preservation number is GDMCC NO. 67441-B1. The invention further discloses a preparation method of the Vibrio campbelli phage vBVcaSR45Z strain. The bacteriophage vBVcaSR45Z has the advantages of rapid splitting capacity, high host inhibition effect, safe genome structure and clear systematic classification status, and provides an important basis for the bacteriophage vBVcaSR45Z as a biological prevention and control factor of aquatic vibrio pathogens.

The invention discloses a human-derived anti-respiratory syncytial virus neutralizing antibody RS135 and application of the human-derived anti-respiratory syncytial virus neutralizing antibody RS135. The human neutralizing antibody specifically aiming at the F protein of the respiratory syncytial virus is successfully obtained by applying a phage antibody library technology; the obtained human neutralizing anti-respiratory syncytial virus F protein gene engineering antibody variable region gene, Fab antibody gene and full antibody gene under the characteristics of each antibody gene are utilized to obtain the human neutralizing anti-respiratory syncytial virus F protein gene engineering antibody. The antibody can be expressed and produced in prokaryotic cells, yeast cells, eukaryotic cells and any recombination system or any other reconstructed gene containing the antibody gene on the basis of the antibody, and an antibody product capable of neutralizing respiratory syncytial virus infection is obtained. And a specific antibody drug for clinically preventing and treating respiratory syncytial virus infection is prepared.

The present invention relates to the technical field of phages. Provided are a KL2-type Acinetobacter baumannii phage and a screening method therefor, a phage composition and the use, and a drug. The KL2-type Acinetobacter baumannii phage is named AB_SZL2, and is deposited in the China Center for Type Culture Collection with the deposit number CCTCC NO: M20241522; or the KL2-type Acinetobacter baumannii phage is named AB_SZL3, and is deposited in the China Center for Type Culture Collection with the deposit number CCTCC NO: M20241523. The KL2-type Acinetobacter baumannii phage can accurately target KL2-type Acinetobacter baumannii, and has an efficient bactericidal effect, thereby reducing the harm of KL2-type Acinetobacter baumannii and effectively addressing the problem of the antibiotic resistance of KL2-type Acinetobacter baumannii.

The invention discloses lactobacillus mucus YF28 and application thereof, and belongs to the technical field of microorganisms. The fermented lactobacillus mucus YF28 is separated from Hu sheep manure, is classified and named as the fermented lactobacillus mucus YF28, and has the preservation number of CCTCC (China Center For Type Culture Collection) NO: M 20252433. The fermented lactobacillus mucilaginosus YF28 has good tolerance in the gastrointestinal environment and can reach the intestinal tract to play a role. The bacterial strain has strong intestinal adhesion capacity, is easy to form a probiotic biological membrane, and is beneficial to intestinal health. The fermented lactobacillus mucus YF28 can promote peristalsis, enrich the abundance of Akkermansia bacteria and bacteriophage thereof, restore the water content of excrement to a normal level, and significantly promote intestinal health. The invention has an application prospect in the development of drugs or health-care foods with the function of relieving constipation and related gastrointestinal symptoms.

The invention discloses a mycobacteriophage and application thereof, and relates to the technical field of bacteriophages. The mycobacteriophage is named as Mycobacter phage BZNK001, is preserved in Guangdong Microbial Culture Collection Center, has a preservation number of GDMCC No: 67907-B1, does not contain antibiotic drug-resistant genes and integrase genes, has excellent biological safety and good environmental tolerance, can maintain high biological activity in a temperature range of 37-50 DEG C under an acid-base condition of pH 5-9, and can be used for preparing the antibiotic drug-resistant gene and integrase gene-containing mycobacteriophage for preventing and treating the antibiotic drug-resistant gene and integrase gene-containing mycobacteriophage for preventing and treating the antibiotic drug-resistant gene and integrase gene-containing mycobacteriophage. The bacillus subtilis has broad-spectrum and high-efficiency non-tuberculous mycobacterium cracking activity, and can effectively crack four clinical key mycobacteria such as mycobacterium abscessus, mycobacterium avium, mycobacterium intracellularis and mycobacterium smegmatis. According to the invention, a mycobacteriophage resource library is enriched, a novel and stable biological prevention and control means is provided for efficient prevention and control of mycobacteria, and the mycobacteriophage has good clinical application and industrialization values.

The application provides a preparation method of a functionalized phage probe and application of the functionalized phage probe in detection of escherichia coli. The functionalized phage is a recombinant phage (M13KO7@SaBP) in which streptavidin binding peptide (SaBP) is fused and expressed at the N terminal of the main capsid protein P8 protein of M13K07 phage. In the application, the gene encoding SaBP (MDVEAWLGAR) is inserted into the N terminal of the P8 protein gene of M13K07 phage by site-directed mutagenesis to prepare M13K07@SaBP. The stable signal amplification is realized by using the abundant P8 protein (about 2700) of M13 phage and the super strong binding force of biotin-streptavidin, the interference of food sample matrix is reduced by combining the magnetic separation technology, and a detection method of escherichia coli with high sensitivity and small sample matrix interference is constructed.

The invention belongs to the technical field of immunodetection, and discloses a preparation and characterization method of a rabbit-derived single-chain antibody for detecting a liver cancer marker GPC3. The rabbit-derived single-chain antibody has the characteristics of small volume, high specificity, high stability and good sensitivity, and can be used in an immunoassay method for detecting a liver cancer marker GPC3; according to the method, a specific rabbit single-chain antibody is obtained through screening, expression and purification by using a phage display technology, a GPC3 antigen is coated on a solid-phase carrier, the rabbit single-chain antibody is used as a detection carrier, the binding force of the single-chain antibody and the antigen is identified, and the method is high in specificity, good in sensitivity and high in specificity. A novel single-chain antibody with high specificity and high sensitivity is provided for detection of GPC3 in serum.

The invention discloses a preparation method and application of a cat main allergen FEL-1 nano antibody FEL-1-Nb, and relates to the technical field of antibody preparation, and the preparation method comprises the following steps: preparing an immunogen; animal immunization and library construction; constructing and panning a phage display library; screening and identifying positive clone; and expression and purification of the nano antibody: cloning the positively cloned VHH gene to an expression vector such as a pET series, transforming an expression strain such as escherichia coli BL21 (DE3), carrying out IPTG induced expression, and purifying through an inclusion body purification method to obtain a high-purity nano antibody protein. The nano antibody FEL-1-Nb provided by the invention can be specifically bound with a cat main allergen FEL-1 protein, the unique amino acid sequence of the nano antibody FEL-1-Nb is shown as SEQIDNO: 1, high-affinity binding with the FEL-1 protein is ensured, the positive clone binding rate is high through phage display panning and ELISA verification, the phage recovery rate after the third round of panning is increased by more than 1000 times compared with the first round of panning, and the positive clone binding rate is higher than that of the first round of panning. Therefore, the nano antibody has excellent targeted recognition capability.

The present invention provides a bacteriophage having a bacteriolytic activity against Mycobacterium avium and / or Mycobacterium intracellularis, the bacteriophage having a genome containing a nucleic acid sequence represented by the genome of the bacteriophage specified by the preservation number NITE BP-03513 or NITE BP-03514 or the preservation number NITE BP-03918, the bacteriophage having a bacteriolytic activity against Mycobacterium avium and / or Mycobacterium intracellularis, and the bacteriophage having a bacteriolytic activity against Mycobacterium avium and / or Mycobacterium intracellularis. The capsid of the phage is connected with the cell-penetrating peptide through a tag.

The application discloses a kind of exogenous bacteriophage inoculation methods for strengthening soil microbial arsenic methylation capacity, comprising the following steps: S1. preparation bacteriophage crude extract;S2. preparation concentrated solution;S3. preparation bacteriophage extract;S4. preparation inoculation soil sample;S5. in the 2, 4, 6th day of culture, bacteriophage extract is added to inoculation soil;S6. after three times inoculation, continue to flood culture 9 days.The application proposes a kind of inoculation method for retaining virulent bacteriophage, not retaining original host bacteria, inoculating after flooding two days, and inoculating three times, so that the proportion of lysogenization of bacteriophage in soil after inoculation is increased by 156%~347%, so that arsenic metabolism genes carried by bacteriophage genome can function, the arsenic methylation capacity of soil microorganism is strengthened, and the arsenic methylation capacity is increased by more than 300%, to efficiently methylate arsenic in soil.

The invention discloses a pasteurella phage PTP1APTYT15 as well as a composition, a kit and application of the pasteurella phage PTP1APTYT15, the pasteurella phage PTP1APTYT15 is preserved in Guangdong Microbial Culture Collection Center on September 10, 2025, the preservation number of the pasteurella phage PTP1APTYT15 is GDMCC NO: 66946-B1, and the pasteurella phage PTP1APTYT15 is classified and named as Pasteurella phage PTP1APTYT15. The pasteurella phage PTP1APTYT15 provided by the invention has the characteristics of high temperature resistance and alkali resistance, and can be used for cracking pasteurella of various serotypes. In addition, the bacteriophage is high in proliferation efficiency and high in splitting capacity, has no adverse effect on human or animal health, and has good biological safety.

This invention belongs to the field of microcystin-LR detection technology, providing anti-microcystin-LR nanobodies and their applications. The anti-microcystin-LR nanobodies have amino acid sequences as shown in SEQ ID NO.1, SEQ ID NO.2, or SEQ ID NO.3. This invention uses phage display technology to screen for nanobodies with high affinity and high specificity for recognizing microcystin-LR, exhibiting advantages such as strong stability and ease of large-scale expression. Various detection tools can be designed based on anti-microcystin-LR, including test strips, immunoassay kits, immunoaffinity columns, biosensor detection chips, or detection probes. This provides novel antibody resources for rapid monitoring of microcystin-LR and lays a material foundation for developing low-cost, high-performance immunoassay technologies, which is of great significance for promoting the monitoring and control of microcystin-LR pollution.

Agricultural compositions are disclosed which comprise at least one isolated bacteriophage capable of infecting the plant pathogen Pseudomonas syringae pv. tomato, the at least one bacteriophage having a genomic nucleic acid sequence at least 85% identical to one of the nucleic acid sequence as set forth in SEQ ID NOs: 1-23. The composition comprises no more than 10 different strains of bacteriophage. Uses thereof for treating bacterial speck disease are also disclosed.

HPV16 is a main cause of malignant tumors such as cervical cancer, and E6 protein of HPV16 becomes a key treatment and diagnosis target. In the prior art, an HPV16 detection antibody has the problems of poor stability, dependence on cold chain transportation, low preparation efficiency and the like. According to the invention, a nano antibody sequence which is high in affinity (dissociation constant KD is less than or equal to 1 * 10 <-7 > M) and stable at room temperature is obtained through total synthesis library construction and a phage-assisted directed evolution (PACE) screening technology. After the antibody is stored at 25 DEG C for 30 days, the activity of the antibody is kept to be greater than or equal to 95%, the antibody can be directly used for household test paper, the accuracy rate reaches 98%, and meanwhile, the antibody can be expanded to medical applications such as CAR-T cell therapy. Compared with a traditional antibody, the antibody has the advantages of being short in preparation period, low in cost, wide in application scene and the like, and a breakthrough solution is provided for early screening of cervical cancer.

The present application belongs to the field of microbial technology, and particularly relates to a bacteriophage preparation for controlling foodborne enterobacter and application thereof, wherein the bacteriophage preparation comprises any one or several of bacteriophage PhiEAS1, bacteriophage PhiEHO11, bacteriophage PhiEHO14 and bacteriophage PhiECL22. The four bacteriophages provided by the present application can be used alone or combined into a bacteriophage cocktail, and the influence of the bacteriophage preparation on enterobacter in different ecologies and environments is explored through bacteriophage cocktail therapy. The results show that the bacteriophage preparation exhibits significant bacteriostatic activity on various food substrates contaminated by Enterobacter hormaechei, such as lettuce, pork, milk, cherry tomato and the like; in an animal model, intraperitoneal injection of the bacteriophage preparation can effectively prevent and treat bacteremia caused by Enterobacter hormaechei, and shows potential as an anti-Enterobacter hormaechei biological control agent.

The invention discloses a human-derived hysteromyoma targeting peptide and application thereof, the sequence of the targeting peptide is selected from SEQ ID NO: 1 to SEQ ID NO: 5, and the SEQ ID NO: 1 (VN12) is the most preferable. The fusion protein is obtained by screening through a phage display technology, and has high hysteromyoma targeting specificity and low immunogenicity. The targeting peptide can be coupled with nuclide or fluorescent dye, and is used for accurate PET imaging, fluorescent diagnosis and intraoperative navigation of hysteromyoma. Experiments prove that the molecular marker is specifically enriched in tumor tissues (the tumor / muscle ratio is 60), the biological safety is good, the problems of insufficient diagnosis sensitivity and large treatment wound in the prior art are solved, and the molecular marker has a great application prospect in diagnosis and treatment of hysteromyoma.

In order to control plant diseases caused by Xanthomonas bacteria, a novel bacteriophage exhibiting bacteriolytic activity specific to the same bacteria is isolated, and a plant disease control composition containing the same as an active ingredient is developed and provided. Provided are a lysozyme containing a bacteriophage having a novel genomic DNA sequence and exhibiting a lysolytic activity specific to Xanthomonas bacteria, and a plant disease control composition containing the lysozyme as an active ingredient.

The invention discloses a novel acinetobacter baumannii phage vBAbaMpha0264 and application thereof, and belongs to the technical field of microorganisms. The acinetobacter baumannii phage vBAbaMpha0264 is preserved in the Guangdong Microbiological Culture Collection Center on August 28, 2025, the preservation number of the acinetobacter baumannii phage vBAbaMpha0264 is GDMCC (China General Microbiological Culture Collection Center) NO: 66893-B1, and the preservation address of the acinetobacter baumannii phage vBAbaMpha0264 is Institute of Microbiology, Academy of Sciences, Guangdong. The bacteriophage vBAbaMpha0264 has high cracking activity, environmental stability and safety, shows a breakthrough host range, and can be used for effectively cracking a plurality of acinetobacter bacteria including hospital acinetobacter and acinetobacter sysei. Meanwhile, the bacteriophage has excellent chloroform tolerance, and the stability of the bacteriophage is obviously superior to that of the existing bacteriophage. Due to the characteristics, the phage vBAbaMpha0264 overcomes the technical prejudice of'narrow spectrum and instability 'of the traditional phage, and a brand new technical scheme is provided for developing a universal antibacterial preparation covering more pathogenic bacteria.

The application discloses an Aeromonas hydrophila bacteriophage and application thereof, and the taxonomic name of the bacteriophage is Aeromonas hydrophila The application discloses an Aeromonas hydrophila bacteriophage and application thereof, and the taxonomic name of the bacteriophage is PTS0531-2, which is preserved in the Guangdong Microbial Culture Collection Center, and the preservation date is March 18, 2026, the preservation number is GDMCC No: 67971-B1, and the preservation address is No. 59, Block 5, 100, Martyrs' Road, Guangzhou. The Aeromonas hydrophila bacteriophage has a strong lysis effect on Aeromonas hydrophila derived from Chinese soft-shelled turtles, and can be used for preventing and controlling Aeromonas hydrophila in a Chinese soft-shelled turtle breeding environment or in vivo.

The invention relates to a bacteriophage, in particular to a cross-host multivalent bacteriophage and preparation and application of a bacteriostatic agent of the bacteriophage, the multivalent bacteriophage is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: M 2026045. The salmonella bacteriophage CCTCC NO: M 2026045 is found for the first time, is a multivalent bacteriophage, can cross-host infect and split multiple important livestock and poultry intestinal pathogens such as salmonella, escherichia coli, shigella, klebsiella pneumoniae and proteus mirabilis, solves the problem of narrow host range of a single bacteriophage, and improves the prevention and control efficiency. By inhibiting the overgrowth of the gram-negative pathogenic bacteria, the intestinal microecological balance can be regulated, so that the aim of effective prevention and control is fulfilled.

Provided are polynucleotides comprising a mobile bacterial island nucleotide sequence (B-INS) comprising one or more modifications (a modified B-INS) that include deletion or modification of restriction enzyme recognition sites to inhibit restriction enzyme cleavage of the B-INS, and an insertion of at least one cargo sequence into the B-INS. The B-INS is packaged within a bacterium into a phage-like particle that contains a bacteriophage capsid, tail and tail fiber proteins. The phage-like particle function as an antibacterial drone "ABD" and infects bacteria. The cargo sequence is introduced into bacteria infected by the ABD and kills the infected bacteria or inhibits growth of infected bacteria.

This invention discloses a polypeptide that specifically binds to the coronavirus S protein, its encoding gene, and its applications, belonging to the field of molecular biology. The polypeptide specifically binding to the coronavirus S protein provided by this invention contains the following amino acid sequence: HFVKTPARWAWG, obtained through screening using phage display technology. The polypeptide provided by this invention can specifically bind to the coronavirus S protein and specifically block the binding of the coronavirus S protein to ACE2, thereby inhibiting coronavirus infection and can be used to prepare anti-coronavirus drugs.

The invention discloses a bacteriophage capable of efficiently splitting Pseudomonas ongdamura and a composition and application thereof, the bacteriophage is Pseudomonas ongdamura bacteriophage PL1P1, the preservation number is CCTCCM20251191, the Pseudomonas ongdamura bacteriophage PL1P1 is a virulent bacteriophage separated from the nature, and the Pseudomonas ongdamura bacteriophage PL1P1 has relatively high tolerance to ultraviolet rays and pH, and can be used for efficiently splitting Pseudomonas ongdamura and Pseudomonas ongdamura and Pseudomonas ongdamura. The bacteriophage is suitable for different prevention and treatment environments and can achieve a good fresh-keeping effect on chilled meat, DNA of the bacteriophage cannot encode protein possibly causing potential health risks, the possibility of carrying lysogenic genes does not exist, the bacteriophage has high affinity and splitting capacity, the titer of 10 < 10 > PFU / mL or above can be achieved within 24 h of culture, and the bacteriophage has good application prospects. The Pseudomonas longdamura phage PL1P1 can specifically partially or completely inactivate Pseudomonas longdamura, can complete mass proliferation only by using a small amount of initial phage, and provides a high-quality phage strain source for industrial production of phage bactericides.

1. Name of the designed product: toy (microscopic life - bacteriophage invasion of animal cells). 2. Use of the designed product: for toys. 3. Design points of the designed product: in the combination of shape and pattern. 4. Picture or photo best indicating the design points: perspective view.

The invention relates to the technical field of bacteriophages, and particularly discloses an acinetobacter baumannii bacteriophage, depolymerases and a preparation method and application of the acinetobacter baumannii bacteriophage. The acinetobacter baumannii bacteriophage P919 provided by the invention has very strong specific lysis capability on KL3 type acinetobacter baumannii, and the coded depolymerases of the acinetobacter baumannii bacteriophage P919 have excellent temperature stability at 70 DEG C or below, and can effectively degrade capsular polysaccharide of the KL3 type acinetobacter baumannii.

The application provides a new bacteriophage for preventing and treating vibrio diseases of aquatic animals and application thereof, the bacteriophage is preserved in China Center for Type Culture Collection on September 4, 2020, and the preservation number is CCTCC M 2020465. The bacteriophage is a new species of bacteriophage of the Caudovirales class and Queuovirinae subfamily, the whole genome of the bacteriophage is OP331229.1 in the NCBI official website GeneBank. The bacteriophage has a wide phage spectrum, can crack 6 different species and genera of vibrio at the same time, can crack 45 strains of Vibrio parahaemolyticus, 22 strains of Vibrio harveyi, 17 strains of Vibrio alginolyticus, 13 strains of Vibrio vulnificus, 11 strains of Vibrio campbellii and 9 strains of Vibrio cholerae at the same time, can more effectively solve the problem of multiple bacterial disease infections in aquaculture, and can be used as a microecological preparation for preventing and treating vibrio diseases such as Vibrio parahaemolyticus, Vibrio harveyi and Vibrio alginolyticus of aquatic animals.